Authors: TRANSON C LECOEUR S LEEMANN T BEAUNE P DAYER P

Citation: C. Transon et al., INTERINDIVIDUAL VARIABILITY IN CATALYTIC ACTIVITY AND IMMUNOREACTIVITY OF 3 MAJOR HUMAN LIVER CYTOCHROME-P450 ISOZYMES, European Journal of Clinical Pharmacology, 51(1), 1996, pp. 79-85

Authors: TRANSON C LEEMANN T DAYER P

Citation: C. Transon et al., IN-VITRO COMPARATIVE INHIBITION PROFILES OF MAJOR HUMAN DRUG-METABOLIZING CYTOCHROME-P450 ISOZYMES (CYP2C9, CYP2D6 AND CYP3A4) BY HMG-COA REDUCTASE INHIBITORS, European Journal of Clinical Pharmacology, 50(3), 1996, pp. 209-215

Authors: TRANSON C LECOEUR S LEEMANN T BEAUNE P DAYER P

Citation: C. Transon et al., INTERINDIVIDUAL VARIATION IN FUNCTION AND IMMUNOREACTIVITY OF 3 MAJORHUMAN LIVER CYTOCHROME-P450 ISOZYMES, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 25-25

Authors: TRANSON C LEEMANN T VOGT N DAYER P

Citation: C. Transon et al., IN-VIVO INHIBITION PROFILE OF CYTOCHROME P450(TB) (CYP2C9) BY (+ -)-FLUVASTATIN/, Clinical pharmacology and therapeutics, 58(4), 1995, pp. 412-417

Authors: TRANSON C VOGT N DAYER P

Citation: C. Transon et al., TRANSIENT INHIBITION OF P450TB (CYP2C) BY FLUVASTATIN IN-VIVO, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 154-154

Authors: LEEMANN TD TRANSON C BONNABRY P DAYER P

Citation: Td. Leemann et al., A MAJOR ROLE FOR CYTOCHROME P450TB (CYP2C SUBFAMILY) IN THE ACTIONS OF NONSTEROIDAL ANTIIFLAMMATORY DRUGS, Drugs under experimental and clinical research, 19(5), 1993, pp. 189-195